NCT02687191View on ClinicalTrials.gov

Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage

PHASE1TerminatedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

January 31, 2018

Study Completion Date

January 31, 2018

Conditions
Intracerebral Hemorrhage
Interventions
BIOLOGICAL

PF-05230907

PF-05230907 IV bolus injection

Trial Locations (13)

15706

Hospital Clínico Universitario de Santiago de Compostela, Area Neurovascular-Neurologia, Santiago de Compostela

17007

Hospital Universitari Dr. Josep Trueta IDIBGI, Department Neurology, Girona

28034

Hospital Universitario Ramon y Cajal, Madrid

43210

James Cancer Hospital and Solove Research Institute, Columbus

The Ohio State University Wexner Medical Center, Columbus

43221

Martha Morehouse Medical Plaza, Columbus

63110

Barnes Jewish Hospital, St Louis

Washington University,, St Louis

K1Y4E9

The Ottawa Hospital, Ottawa

H3A2B4

Montreal Neurological Institute and Hospital, Montreal

08916

Hospital Universitari Germans Trias i Pujol, Badalona

08035

Hospital Vall d'Hebron, Unidad de Ictus, Barcelona

NW1 2BU

University College Hospital, London

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02687191 - Safety and Tolerability of PF-05230907 in Intracerebral Hemorrhage | Biotech Hunter | Biotech Hunter